Press Release: Strictly Embargoed Until 00.01 Hours (BST), Wednesday, July 22, 2015
[19.01 Hours US Eastern Time, July 21 / 09.01 Hours Australian Eastern Standard Time (AEST), July 22]
Media contacts:
Wiley: Evelyn Martinez (US): +1 201 748 6358+1 201 748 6358
sciencenewsroom@wiley.com
Cochrane Library
Cochrane Press Office: Jo Anthony (UK): +44 (0) 7582 726 634+44 (0) 7582 726 634
janthony@cochrane.org or pressoffice@cochrane.org
A new review published in the Cochrane Library indicates that eradicating Helicobacter pylori (H. pylori) bacteria - the main cause of stomach ulcers - with a short course of therapy comprising two commonly used medicines may help to reduce the risk of gastric cancer. Stomach, or gastric, cancer is the third most common cause of death from cancer worldwide, and people who are infected with the H. pylori bacterium are more likely to develop the disease.
About two-thirds of us have H. pylori in our bodies, but in most cases we experience no discomfort or other symptoms. However, it can be eradicated with a simple short course of antibiotics, often used with another medicine that suppresses the production of gastric acid. To determine whether eliminating H. pylori might reduce the incidence of gastric cancer, researchers analyzed all published randomized controlled trials comparing at least one week of H. pylori therapy with placebo or no treatment in otherwise healthy and asymptomatic H. pylori-positive adults. The review included only trials that followed participants for at least two years and that had at least two participants who developed gastric cancer.
Six trials with a total of nearly 6500 participants met the researchers’ criteria. One study was conducted in Colombia and the remainder were conducted in Asian countries, with four in China and one in Japan where stomach cancer is more common. The studies mainly used a combination of antibiotics with medicines from a class of drugs that suppress gastric acid production (proton pump inhibitors). An analysis of the studies’ results revealed that combining antibiotics with gastric acid suppressor therapy given for between one and two weeks prevented the development of gastric cancer compared with placebo or no treatment: in the studies, 51/3294 (1.6%) of the people given H. pylori treatment developed gastric cancer compared with 76/3203 (2.4%) given no treatment or a placebo. However, the number of deaths from gastric cancer in the trials was low, and there was insufficient evidence to be certain whether eradication improved survival.
“The findings of this systematic review and meta-analysis add to the increasing evidence that eradicating H. pylori in the general population has the potential to prevent gastric cancer. International guidelines for the management of H. pylori infection may change as a result,” said co-author Paul Moayyedi, of McMaster University, in Canada. “More research is needed on the extent of this effect and on any potential harms of H. pylori treatment before it can be advocated as a means of preventing gastric cancer.“
“The review highlights the need for further trials in different populations to provide more evidence, and these should report both the benefits and harms of such an approach,” said lead author Alex Ford, of St. James’s University Hospital and Leeds University in the UK.
Access the full study on the Wiley Press Room here. (To access PDFs and embargoed stories you must be logged in to the Press Room before clicking the link. Request a login here.)
Full citation: Ford AC, Forman D, Hunt R, Yuan Y, Moayyedi P. Helicobacter pylori eradication for the prevention of gastric neoplasia. Cochrane Database of Systematic Reviews 2015, Issue 7. Art. No.: CD005583. DOI: 10.1002/14651858.CD005583.pub2
URL Upon publication: http://doi.wiley.com/10.1002/14651858.CD005583.pub2
For further information: Please contact Susan Emigh, Director, Public Relations, Faculty of Health Sciences, McMaster University, Tel: 905-525-9140905-525-9140, ext. 22555, Cell: 905-518-3642905-518-3642, emighs@mcmaster.ca, or Jo Anthony, Senior Media and Communications Officer, Cochrane at M +44(0) 7582 726 634+44(0) 7582 726 634 or janthony@cochrane.org, pressoffice@cochrane.org.
About Cochrane
Cochrane is a global independent network of researchers, professionals, patients, carers, and people interested in health. Cochrane produces reviews which study all of the best available evidence generated through research and make it easier to inform decisions about health. These are called systematic reviews. Cochrane is a not-for profit organization with collaborators from more than 120 countries working together to produce credible, accessible health information that is free from commercial sponsorship and other conflicts of interest. Our work is recognized as representing an international gold standard for high quality, trusted information. Find out more at http://cochrane.org Follow us on twitter @cochranecollab
About Wiley
Wiley is a global provider of knowledge and knowledge-enabled services that improve outcomes in areas of research, professional practice, and education. Through the Research segment, the Company provides digital and print scientific, technical, medical, and scholarly journals, reference works, books, database services, and advertising. The Professional Development segment provides digital and print books, online assessment and training services, and test prep and certification. In Education, Wiley provides education solutions including online program management services for higher education institutions and course management tools for instructors and students, as well as print and digital content. The Company's website can be accessed at http://www.wiley.com.
If you would like to request complimentary media access to the contents of The Cochrane Library, please email sciencenewsroom@wiley.com.